As shown in Figures 3(m) and 3(n), the RFS and DMFS of breast cancer patients in the MYL5 high-expression group were significantly longer than the MYL5 low-expression group, which kept in with the survival data from the Kaplan–Meier plotter dataset and these data further indicated that MYL5 served as a potential and favorable biomarker on diagnosis in breast cancer. The gene discussed is MYL5; the disease is breast carcinoma.